headache

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial

Study Overview The research presented focuses on evaluating the efficacy and safety of a fixed-dose combination of daily doravirine (100

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial Read Post »

Commentary on “Examining and Comparing the Clinical Characteristics of Adults with Persisting Post-Concussion Symptoms Presenting for Outpatient Rehabilitation Following a Mild Traumatic Brain Injury or a Minimal Head Injury”

Clinical Characteristics of Patients The clinical characteristics of patients exhibiting persisting post-concussion symptoms (PPCS) present a diverse and complex picture.

Commentary on “Examining and Comparing the Clinical Characteristics of Adults with Persisting Post-Concussion Symptoms Presenting for Outpatient Rehabilitation Following a Mild Traumatic Brain Injury or a Minimal Head Injury” Read Post »

Scroll to Top